Business Wire

09 Jun 2026, 10:30 UTC · 2h ago

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Read original · https://www.businesswire.com/news/home/20260609079857/en/Four%E2%80%91Year-BIOMAG%E2%84%A2-I-Study-Results-Presented-at-EuroPCR-Confirm-Long%E2%80%91Term-Safety-and-Sustained-Performance-of-the-Freesolve%E2%84%A2-Resorbable-Magnesium-Scaffold-DREAMS-3G/

Top 1 mover · tap to explore

Story key points

1 claims · impact-rated

What matters in this story

1
Teleflex's BIOMAG-I clinical study demonstrated a favorable long-term safety profile in four-year follow-up data. — Positive long-term clinical data reduces regulatory and safety risk for the product, supporting potential future adoption and revenue growth.
+0.30

Ticker attribution

Model heads

Sentiment in this article

TFX+0.60
The company announced favorable long-term safety data from its BIOMAG-I Clinical Study.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

Impact vectors

6 related stories

GlobeNewsWire
2h ago
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
- clinical trial
- healthcare
- medical devices
Read

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑T… · News Impact Screener

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

4DMedical Limited (FDMDF) M&A Call Transcript

Medtronic: A Dividend Aristocrat At A Steal Now

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

AI Bulls Are Back in the Driving Seat as Stock Market Sidelines Bubble Fears

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

4DMedical Limited (FDMDF) M&A Call Transcript

Medtronic: A Dividend Aristocrat At A Steal Now

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

AI Bulls Are Back in the Driving Seat as Stock Market Sidelines Bubble Fears